2021 Archives - Raglan Capital

Open Orphan co-founder Carol Dalton on how a timely deal turned a pandemic into an opportunity

Open Orphan subsidiary develops human study for malaria

Surprise! Pfizer jumps the queue and leaps into RSV vax contention as COVID helps turbocharge work

The Executive Chairman of Open Orphan plc (LON:ORPH), Cathal Friel, Just Bought 2.5% More Shares

BRIEF—COVID-19 human challenge study to expand

Open Orphan launches infectious disease spinout

Our flu drug is not to be sniffed at, says Poolbeg Pharma chief Jeremy Skillington

Luke O’Neill joins Open Orphan spin-off ahead of pharma firm’s IPO

Poolbeg to cash in on disease interest at IPO roadshow

Open Orphan spin-out Poolbeg Pharma to list on London market